Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Breyanzi Is Third To Market, But BMS’s First CAR-T Therapy Priced Above Competitors
Third Cell Therapy For Lymphoma Approved In The US
Feb 08 2021
•
By
Mary Jo Laffler
and
Mandy Jackson
Breyanzi was approved after an FDA delay related to manufacturing inspections • Source: Shutterstock
Keep up with the top pharma business news of the week. On the go.
Scrip brings you a weekly bulletin of top picks.
More from New Products
More from Scrip